Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Stan Gill"'
Autor:
Raoul Tibes, Stan Gill, Chaofeng Liu, Christoph Röllig, Stephen A. Strickland, Joseph G. Jurcic, Stuart L. Goldberg, Maria R. Baer, Alexander E. Perl, Alexander I. Spira, Andreas Neubauer, Gary J. Schiller, Mark R. Litzow, Richard A. Larson, Catherine C. Smith, Jessica K. Altman, Harry P. Erba, Mark J. Levis, Erkut Bahceci, Giovanni Martinelli, Robert K. Stuart, Eunice S. Wang, Jorge E. Cortes, David F. Claxton, Celalettin Ustun, Ellen K. Ritchie
Publikováno v:
The Lancet. Oncology, vol 18, iss 8
The Lancet. Oncology
The Lancet. Oncology
Summary Background Internal tandem duplication mutations in FLT3 are common in acute myeloid leukaemia and are associated with rapid relapse and short overall survival. The clinical benefit of FLT3 inhibitors in patients with acute myeloid leukaemia
Publikováno v:
Reproductive Toxicology. 30:619-624
We determined the toxicity of faropenem medoxomil (FPM) in neonatal/juvenile dogs following 28 days of administration. The puppies received vehicle or FPM beginning on Postnatal Day (PND) 22 at respective dose levels of 0, 100, 300, 600, or 1400 mg/k
Publikováno v:
Regulatory Toxicology and Pharmacology. 55:28-32
The purpose of this study was to evaluate the potential irritating effects and the systemic exposure level of an antibacterial ointment containing REP8839 as a single agent or in combination with mupirocin versus Bactroban Nasal in rabbits. Additiona
Autor:
Stan Gill, Julie D. Horan, Margaret A. Foley, Stergios Zacharoulis, Daniel C. Bowers, Mark W. Kieran, Eric Bouffet, Jiuzhou Wang, Regina I. Jakacki
Publikováno v:
Journal of neuro-oncology. 129(1)
Overexpression of human epidermal growth factor receptor (HER/EGFR) is associated with various tumors, including ependymomas. To investigate whether EGFR inhibition was of benefit in pediatric patients with recurrent ependymoma, a multi-center, rando
Autor:
Nasser K. Altorki, Frances A. Shepherd, Jun Wu, Mary O'Brien, Stan Gill, Frank C. Richardson, Julie D. Horan, Wilfried Eberhardt, Kenneth K. Iwata, Karen Kelly, Margaret A. Foley, Joe Wang
7539 Background: Data on EGFRm in early stage NSCLC are limited. RADIANT was a prospectively randomized Phase 3 trial of adjuvant erlotinib (E) v placebo (P) in 973 patients (pts) with completely r...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b61a0fe1cccc701491be4b6098837a92
Autor:
Stan Gill, Augusta E. Garrison, Ray A. Bendele, Julie Wolf, S Knauer, Lotus Moon-McDermott, Dorothy B. Colagiovanni
Publikováno v:
Journal of Liposome Research. 11:243-254
Traditional therapies for Staphylococcal infections such as osteomyelitis or localized abscesses have a difficult time penetrating into tissue sites. To effectively ameliorate these infections, prolonged therapy and/or high doses of antibiotics are f
Autor:
Jaap Verweij, Walter J. Loos, Stan Gill, Peter de Bruijn, Marta Hamilton, Kees Nooter, Alex Sparreboom, Eric Brouwer, Diederik F. S. Kehrer, Gerrit Stoter
Publikováno v:
Journal of Chromatography B-Biomedical Applications, 738, 155-163. Elsevier
Lurtotecan (GI147211; LRT) is a semisynthetic and water-soluble analogue of the topoisomerase I inhibitor camptothecin. To determine whether the therapeutic efficacy of LRT in patients could be improved, the drug was encapsulated in liposomes (NX211;
Autor:
Charles Liu, Takeshi Kadokura, Jessica K. Altman, Alexander E. Perl, Catherine C. Smith, Geoffrey Yuen, Angela Joubert James, Peter L. Bonate, Erkut Bahceci, Itsuro Nagase, Ogert Fisniku, Mark J. Levis, Mark R. Litzow, Stan Gill
Publikováno v:
Journal of Clinical Oncology. 34:7026-7026
7026Background: Gilteritinib, also known as ASP2215, is a selective FLT3 inhibitor in development for the treatment of acute myeloid leukemia (AML). In ongoing trials, gilteritinib has demonstrated...
Autor:
David F. Claxton, Jessica K. Altman, Maria R. Baer, Mark R. Litzow, Charles Liu, Alexander E. Perl, Jorge E. Cortes, Richard A. Larson, Catherine C. Smith, Stan Gill, Ellen K. Ritchie, Briana Sargent, Stephen A. Strickland, Gary J. Schiller, Mark J. Levis, Celalettin Ustun, Erkut Bahceci, Eunice S. Wang
Publikováno v:
Journal of Clinical Oncology. 33:7003-7003
7003 Background: FLT3 Internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations are seen in 30% of AML patients (pts) and are associated with poor survival. Secondary FLT3-TKD mu...
Autor:
Chris Twelves, Stan Gill, Hilary Glen, Gernot Beutel, J. Chick, Patrick Schöffski, Jim Cassidy
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 11(15)
Purpose: OSI-7904L is a liposomal formulation of a potent noncompetitive thymidylate synthase inhibitor (TSI) that does not require polyglutamation for activity. This phase I study was done to establish the safety, tolerability, maximum tolerated dos